Zealand Pharma A/S (ZLDPF)
USD 113.28
(0.0%)
USD 113.28
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 102.57 Million DKK | -76.08% |
| 2022 | 428.74 Million DKK | -44.5% |
| 2021 | 772.53 Million DKK | 612.3% |
| 2020 | 108.45 Million DKK | 38.93% |
| 2019 | 78.06 Million DKK | 0.0% |
| 2018 | - DKK | -100.0% |
| 2017 | 132.98 Million DKK | -59.56% |
| 2016 | 328.87 Million DKK | 5.09% |
| 2015 | 312.95 Million DKK | 17.14% |
| 2014 | 267.17 Million DKK | 0.0% |
| 2013 | - DKK | 0.0% |
| 2012 | - DKK | 0.0% |
| 2011 | - DKK | 0.0% |
| 2010 | - DKK | 0.0% |
| 2009 | - DKK | 0.0% |
| 2008 | - DKK | -100.0% |
| 2007 | 1.12 Million DKK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 276.79 Million DKK | 1.54% |
| 2024 Q1 | 272.59 Million DKK | 0.0% |
| 2023 FY | 102.57 Million DKK | -76.08% |
| 2023 Q3 | 101.08 Million DKK | -0.97% |
| 2023 Q2 | 102.07 Million DKK | -79.49% |
| 2023 Q1 | 497.72 Million DKK | 16.09% |
| 2023 Q4 | 102.57 Million DKK | 1.47% |
| 2022 Q1 | 776.98 Million DKK | 0.58% |
| 2022 FY | 428.74 Million DKK | -44.5% |
| 2022 Q4 | 428.74 Million DKK | -10.83% |
| 2022 Q3 | 480.81 Million DKK | 1.95% |
| 2022 Q2 | 471.59 Million DKK | -39.3% |
| 2021 Q2 | 128.76 Million DKK | 12.69% |
| 2021 FY | 772.53 Million DKK | 612.3% |
| 2021 Q4 | 772.53 Million DKK | 510.67% |
| 2021 Q3 | 126.5 Million DKK | -1.76% |
| 2021 Q1 | 114.26 Million DKK | 5.36% |
| 2020 Q1 | 91.23 Million DKK | 16.86% |
| 2020 Q3 | 119.29 Million DKK | -2.7% |
| 2020 Q4 | 108.45 Million DKK | -9.08% |
| 2020 FY | 108.45 Million DKK | 38.93% |
| 2020 Q2 | 122.59 Million DKK | 34.38% |
| 2019 Q3 | - DKK | 0.0% |
| 2019 Q1 | - DKK | 0.0% |
| 2019 Q2 | - DKK | 0.0% |
| 2019 FY | 78.06 Million DKK | 0.0% |
| 2019 Q4 | 78.06 Million DKK | 0.0% |
| 2018 Q4 | - DKK | 0.0% |
| 2018 Q2 | 143.43 Million DKK | 9.61% |
| 2018 FY | - DKK | -100.0% |
| 2018 Q1 | 130.86 Million DKK | -1.6% |
| 2018 Q3 | - DKK | -100.0% |
| 2017 Q4 | 132.98 Million DKK | 6.07% |
| 2017 FY | 132.98 Million DKK | -59.56% |
| 2017 Q3 | 125.37 Million DKK | -11.95% |
| 2017 Q2 | 142.39 Million DKK | 12.54% |
| 2017 Q1 | 126.52 Million DKK | -61.53% |
| 2016 Q1 | 301.93 Million DKK | -3.52% |
| 2016 FY | 328.87 Million DKK | 5.09% |
| 2016 Q4 | 328.87 Million DKK | 9.57% |
| 2016 Q3 | 300.14 Million DKK | 1.02% |
| 2016 Q2 | 297.11 Million DKK | -1.59% |
| 2015 Q2 | 296.11 Million DKK | -2.49% |
| 2015 FY | 312.95 Million DKK | 17.14% |
| 2015 Q3 | 328.23 Million DKK | 10.85% |
| 2015 Q1 | 303.68 Million DKK | 13.67% |
| 2015 Q4 | 312.95 Million DKK | -4.66% |
| 2014 Q3 | - DKK | 0.0% |
| 2014 FY | 267.17 Million DKK | 0.0% |
| 2014 Q4 | 267.17 Million DKK | 0.0% |
| 2014 Q2 | - DKK | 0.0% |
| 2014 Q1 | - DKK | 0.0% |
| 2013 FY | - DKK | 0.0% |
| 2013 Q1 | - DKK | 0.0% |
| 2013 Q4 | - DKK | 0.0% |
| 2013 Q3 | - DKK | 0.0% |
| 2013 Q2 | - DKK | 0.0% |
| 2012 Q3 | - DKK | 0.0% |
| 2012 Q1 | - DKK | 0.0% |
| 2012 Q4 | - DKK | 0.0% |
| 2012 Q2 | - DKK | 0.0% |
| 2012 FY | - DKK | 0.0% |
| 2011 FY | - DKK | 0.0% |
| 2011 Q3 | - DKK | 0.0% |
| 2011 Q1 | - DKK | 0.0% |
| 2011 Q2 | - DKK | 0.0% |
| 2011 Q4 | - DKK | 0.0% |
| 2010 Q4 | - DKK | 0.0% |
| 2010 FY | - DKK | 0.0% |
| 2009 FY | - DKK | 0.0% |
| 2008 FY | - DKK | -100.0% |
| 2007 FY | 1.12 Million DKK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -390.578% |
| Evofem Biosciences, Inc. | 8000.00 USD | -1282087.5% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -5743.135% |
| Mesoblast Limited | 100.29 Million USD | -2.273% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -174817.295% |
| Genus plc | 228.2 Million USD | 55.05% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -15275.587% |
| ContraFect Corporation | 2.21 Million USD | -4541.403% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -7211.463% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -1790.268% |
| MultiCell Technologies, Inc. | 36.43 USD | -281567289.514% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -84.448% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -4508.041% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -8250.558% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 38.247% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -5303.041% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -59804.806% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -1860839.768% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | -274.381% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -31755.59% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.087% |
| Halberd Corporation | 150 Thousand USD | -68283.333% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -34091.667% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -62367.647% |
| argenx SE | 15.35 Million USD | -568.067% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -404.997% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -2301852.424% |
| Genscript Biotech Corporation | 287.12 Million USD | 64.276% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -81114.074% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -44635.729% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -18395.645% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -405350.808% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -1141.227% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -38515.017% |
| ONE Bio Corp. | 592.19 Thousand USD | -17221.065% |
| Reve Technologies, Inc. | 1064.00 USD | -9640407.519% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -68459.76% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -68459.76% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -44557.823% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -72648.227% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -128118.75% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -1211.707% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -27694.412% |
| International Stem Cell Corporation | 445 Thousand USD | -22950.562% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -1158.589% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -22345.295% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -8735.056% |
| PureTech Health plc | 18.25 Million USD | -462.055% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -68283.333% |
| IXICO plc | 275 Thousand USD | -37200.0% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -766.416% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -289.886% |
| CSL Limited | 11.23 Billion USD | 99.087% |
| Cellectis S.A. | 36.21 Million USD | -183.269% |